Share

Development and Validation of a new quantitative analytical method of ponatinib in human plasma and CSF using LC-MS/MS

Project objectives

  • Monitoring plasma concentrations of ponatinib in the plasma of patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) Ph+ resistant or intolerant to previous therapy with tyrosine kinase inhibitors.
  • Monitoring of ponatinib concentrations in the cerebrospinal fluid of patients with ALL localized in the CNS.

Start and end date
March 2018 - March 2020

Project Manager
Prof. Girogio Minotti, Head of Pharmaceutical Sciences UR, Università Campus Bio-Medico di Roma and Fondazione Policlinico Universitario Campus Bio-Medico, Rome - Principal Investigator
Prof. Pierantonio Menna, UR Clinical Pharmacology, Department of Science and Technology for Sustainable Development and One Health, Università Campus Bio-Medico di Roma; Campus Bio-Medico University Polyclinic Foundation - Co-Principal Investigator:
prof Emanuela Salvatorelli, UR Pharmaceutical Sciences, Campus Bio-Medico University, Rome - Co-Principal Investigator

Coordinating institution of the project
UR Pharmaceutical Sciences, Departmental Faculty of Medicine and Surgery, Integrated Research Center, Campus Bio-Medico University, Rome

Other Institutions involved
  • IRCCS National Cancer Institute “Regina Elena”, Rome

Funding source(s).
• INCYTE Europe
2023© Università Campus Bio-Medico di Roma, Via Álvaro del Portillo, 21 - 00128 Rome, Tel. +39 06.22541.1, Fax +39 06.22541.456, VAT number: 048 020 51 005, Fiscal Code: 97087620585
QUICK LINKS
L'Università Campus Bio-Medico di Roma promotes integrated teaching and research structures, pursuing the good of the person as the main aim of its activities.
magnifiercrossmenuchevron-downchevron-leftchevron-right